Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COEP Coeptis Therapeutics	$11.48 +5.7%	$9.53	$2.31 ▼ $13.70	$38.16M	-0.59	60,032 shs	48,090 shs
KPRX Kiora Pharmaceuticals	$2.53 +1.6%	$2.89	$2.25 ▼ $4.29	$8.55M	-0.64	76,986 shs	59,876 shs
LVTX LAVA Therapeutics	$1.54 +0.7%	$1.40	$0.85 ▼ $2.09	$40.25M	0.5	155,712 shs	105,979 shs
XLO Xilio Therapeutics	$0.70 -1.7%	$0.69	$0.62 ▼ $1.70	$37.01M	-0.15	421,632 shs	415,714 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COEP Coeptis Therapeutics	+5.71%	+8.30%	+16.67%	+17.02%	+171.65%
KPRX Kiora Pharmaceuticals	+1.61%	+5.86%	-15.67%	-21.67%	-18.39%
LVTX LAVA Therapeutics	+0.65%	+0.65%	+10.00%	+23.20%	-12.99%
XLO Xilio Therapeutics	-1.68%	+7.22%	-1.46%	-18.23%	-14.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COEP Coeptis Therapeutics	0.5018 of 5 stars	0.0	3.0	1.9	1.7	0.0
KPRX Kiora Pharmaceuticals	3.4776 of 5 stars	3.5	5.0	3.1	1.7	0.6
LVTX LAVA Therapeutics	1.9976 of 5 stars	3.0	5.0	2.2	0.0	0.0
XLO Xilio Therapeutics	2.8464 of 5 stars	3.7	2.0	2.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	3.00	Buy	$10.00	295.26% Upside
LVTX LAVA Therapeutics	2.00	Hold	$2.69	74.35% Upside
XLO Xilio Therapeutics	3.33	Buy	$3.00	326.92% Upside

Current Analyst Ratings Breakdown

Latest KPRX, COEP, XLO, and LVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	XLO Xilio Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	XLO Xilio Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$2.00
8/5/2025	LVTX LAVA Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$1.50 ➝ $1.24
8/5/2025	LVTX LAVA Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$3.00 ➝ $1.50
5/15/2025	LVTX LAVA Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
KPRX Kiora Pharmaceuticals	$16.02M	0.54	$1.26 per share	2.01	$6.44 per share	0.39
LVTX LAVA Therapeutics	$11.98M	3.38	N/A	N/A	$1.06 per share	1.45
XLO Xilio Therapeutics	$6.34M	5.74	N/A	N/A	$0.40 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-282.39%	-127.23%	N/A
KPRX Kiora Pharmaceuticals	$3.60M	-$2.91	N/A	N/A	N/A	N/A	-47.17%	-34.00%	N/A
LVTX LAVA Therapeutics	-$25.11M	-$1.04	N/A	N/A	N/A	N/A	-98.08%	-36.06%	8/19/2025 (Estimated)
XLO Xilio Therapeutics	-$58.24M	-$0.84	N/A	N/A	N/A	-585.54%	-262.69%	-64.01%	N/A

Latest KPRX, COEP, XLO, and LVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COEP Coeptis Therapeutics	N/A	-$1.17	N/A	-$1.17	N/A	N/A
8/14/2025	Q2 2025	XLO Xilio Therapeutics	-$0.08	-$0.16	-$0.08	-$0.16	$8.21 million	$8.21 million
8/13/2025	Q2 2025	LVTX LAVA Therapeutics	-$0.28	-$0.32	-$0.04	-$0.32	N/A	N/A
8/8/2025	Q2 2025	KPRX Kiora Pharmaceuticals	-$0.58	-$0.54	+$0.04	-$0.54	$0.75 million	$0.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LVTX LAVA Therapeutics	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COEP Coeptis Therapeutics	0.02	0.82	0.82
KPRX Kiora Pharmaceuticals	N/A	7.76	5.14
LVTX LAVA Therapeutics	N/A	6.73	6.73
XLO Xilio Therapeutics	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COEP Coeptis Therapeutics	13.88%
KPRX Kiora Pharmaceuticals	76.97%
LVTX LAVA Therapeutics	N/A
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
COEP Coeptis Therapeutics	24.25%
KPRX Kiora Pharmaceuticals	0.05%
LVTX LAVA Therapeutics	9.50%
XLO Xilio Therapeutics	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
KPRX Kiora Pharmaceuticals	10	3.43 million	3.43 million	Not Optionable
LVTX LAVA Therapeutics	60	26.31 million	23.81 million	Optionable
XLO Xilio Therapeutics	70	51.78 million	49.09 million	Not Optionable

KPRX, COEP, XLO, and LVTX Headlines

Recent News About These Companies

Xilio Therapeutics reports Q2 EPS (16c) vs (24c) last year

5 hours ago | msn.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

5 hours ago | taiwannews.com.twT

Xilio Revenue Jumps 246 Percent in Q2

5 hours ago | aol.comA

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates

August 14 at 9:36 AM | zacks.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results

August 14 at 7:30 AM | globenewswire.com

Xilio Therapeutics (XLO) Expected to Announce Quarterly Earnings on Thursday

August 12 at 3:27 AM | americanbankingnews.com

Brokers Set Expectations for XLO Q2 Earnings

August 10, 2025 | americanbankingnews.com

Leerink Partners Begins Coverage on Xilio Therapeutics (NASDAQ:XLO)

August 8, 2025 | americanbankingnews.com

Leerink Partners Initiates Coverage of Xilio Therapeutics (XLO) with Outperform Recommendation

August 7, 2025 | msn.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

James Samuel Shannon Acquires 25,000 Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) Stock

June 19, 2025 | insidertrades.com

Xilio Therapeutics expands board, elects new director

June 12, 2025 | investing.com

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors

June 10, 2025 | quiverquant.comQ

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

June 10, 2025 | globenewswire.com

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

June 5, 2025 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

June 2, 2025 | globenewswire.com

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite ...

June 2, 2025 | stockhouse.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPRX, COEP, XLO, and LVTX Company Descriptions

Coeptis Therapeutics NASDAQ:COEP

$11.48 +0.62 (+5.71%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$11.50 +0.03 (+0.22%)

As of 08/14/2025 06:44 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.53 +0.04 (+1.61%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$2.54 +0.01 (+0.36%)

As of 05:26 AM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

LAVA Therapeutics NASDAQ:LVTX

$1.54 +0.01 (+0.65%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.52 -0.02 (-1.56%)

As of 05:29 AM Eastern

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Xilio Therapeutics NASDAQ:XLO

$0.70 -0.01 (-1.68%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.71 +0.01 (+1.18%)

As of 08/14/2025 07:38 PM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time